文献速递造血干细胞移植与细胞治疗淋巴瘤

肿瘤细胞CD58缺失导致CAR T细胞功能受损

CD58 loss in tumor cells confers functional impairment of CAR T cells.
PubMed 文献 · Blood Adv · 2022-01-01

研究通过全基因组CRISPR/Cas9筛选发现并验证肿瘤细胞CD58缺失可在体外和体内导致CAR T细胞免疫逃逸。CD58是T细胞共刺激分子CD2的配体,其突变或表达下调在血液肿瘤中常见。CD58破坏诱导与CAR T细胞形成次优免疫突触,导致CAR T细胞扩增、脱颗粒、细胞因子分泌和细胞毒性减弱。

要点

  • 全基因组CRISPR/Cas9筛选发现肿瘤细胞CD58缺失可导致CAR T细胞免疫逃逸。
  • CD58是T细胞共刺激分子CD2的配体,其突变或表达下调在血液肿瘤中常见。
  • CD58破坏诱导次优免疫突触形成,减弱CAR T细胞扩增、脱颗粒、细胞因子分泌和细胞毒性。

核心结论

  • 研究描述了肿瘤内在对CAR T细胞治疗耐药的潜在机制,并提示该机制可用于开发克服B细胞恶性肿瘤中CAR T细胞治疗耐药的治疗策略。

研究设计与样本

  • 研究采用无偏全基因组CRISPR/Cas9筛选,并在体外和体内验证CD58缺失导致CAR T细胞免疫逃逸。

主要发现

  • 肿瘤细胞中CD58破坏诱导与CAR T细胞形成次优免疫突触,导致CAR T细胞扩增、脱颗粒、细胞因子分泌和细胞毒性减弱。
  • CD58是T细胞共刺激分子CD2的配体,CD58突变或表达下调在血液肿瘤中常见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in treating a variety of hematologic malignancies, but resistance to this treatment in some patients limited its wider application. Using an unbiased genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) screening, we identified and validated loss of CD58 conferred immune evasion from CAR T cells in vitro and in vivo. CD58 is a ligand of the T-cell costimulatory molecule CD2, and CD58 mutation or downregulated expression is common in hematological tumors. We found that disruption of CD58 in tumor cells induced the formation of suboptimal immunological synapse (IS) with CAR T cells, which conferred functional impairment of CAR T cells, including the attenuation of cell expansion, degranulation, cytokine secretion, and cytotoxicity. In summary, we describe a potential mechanism of tumor-intrinsic resistance to CAR T-cell therapy and suggest that this mechanism may be leveraged for developing therapeutic strategies to overcome resistance to CAR T-cell therapy in B-cell malignancies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yan X, Chen D, Ma X, et al. CD58 loss in tumor cells confers functional impairment of CAR T cells. Blood Adv. 2022. PMID: 35728062. doi:10.1182/bloodadvances.2022007891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。